Biotech will continue to deliver 'double-digit growth' - Daniel Koller

clock • 2 min read

BB Biotech's Head of Investment, Daniel Koller, explains why the sector's fundamentals are all lined up to the upside.

Partner insight Regulatory approvals of biotech drugs, ongoing takeover activity, and successful clinical trials involving new treatment approaches are three reasons why savvy investors should be looking at biotech, according to Daniel Koller. Speaking to Investment Week, the manager of the BB Biotech AG trust said advances in biology and science are creating tangible benefits for patients and there are lots of opportunities to do in-depth, fundamental analysis on product launch trends and clinical data events. And M&A is bouncing back. Big Pharma has over $500 billion in cash to depl...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Equities

Deep Dive: US equities may not have peaked but do require greater selectivity

Deep Dive: US equities may not have peaked but do require greater selectivity

Amid equity rebalancing

Linus Uhlig
clock 13 June 2025 • 4 min read
Partner Insight: Robeco Emerging Markets Equities strategy - Targeting alpha in a new world of growth

Partner Insight: Robeco Emerging Markets Equities strategy - Targeting alpha in a new world of growth

Jan de Bruijn, Director, Emerging Market Equities, Robeco
clock 06 June 2025 • 5 min read
Nedgroup Investments' Rob Burdett: It is time to move underweight equities

Nedgroup Investments' Rob Burdett: It is time to move underweight equities

Reducing exposure

Rob Burdett
clock 03 June 2025 • 2 min read
Trustpilot